Most Recent
Aldi has failed in its attempt to block applications for three 'Alby' trade marks filed by a Western Australian craft brewery, thanks to the supermarket chain's lack of reputation for selling beer in Australia.
Hytera will take another shot at winning court approval to amend its defence so it can blame Motorola for not alerting it to the alleged theft of the US telco's source code by former employees sooner.
A simmering battle over the 'oro' trade mark has bubbled over, with Australian coffee giant Vittoria filing Federal Court proceedings alleging Italian competitor Lavazza has knowingly violated its trade mark for the Italian word gold.
State Street Global Advisors has been given the go-ahead to use evidence unearthed in its trade mark and copyright action against Maurice Blackburn over the iconic Fearless Girl statue as evidence in a related US lawsuit against the sculpture's creator.
A settlement has been reached in an intellectual property lawsuit brought by famed Melbourne pub The Corner Hotel against McDonald's alleging the fast food chain's experimental hipster cafe in Sydney violates its "Corner" trade marks.
Gaming giant Aristocrat Technologies told a court that if its Lightning Link slot machine was a physical game there would be no doubt about its patentability, as trial kicked off Monday in another case that is pushing back on IP Australia's stance on the patentability of computer-implemented inventions.
A mortgage broker has successfully opposed REA Group's application to trade mark "realestate.com.au Home Loans", with a delegate finding the mark is not adapted to distinguish REA's online services.
Merck Sharp & Dohme has emerged victorious in a battle over documents with Wyeth, as the parties gear up for a hearing on Wyeth's request to reopen a trial over three patents for its Prevnar 13 pneumococcal vaccine.
Two units of US pharmaceutical giant Pfizer have filed a lawsuit seeking damages from Juno Pharmaceuticals for allegedly infringing the patent for post-operative pain drug Dynastat.
US biotechnology company Regeneron Pharmaceuticals has filed a Federal Court challenge after losing its opposition to a patent application by UK biopharmaceutical company Kymab for a method of producing an animal with part-human DNA.